Support
DONATE
DONATE
Advocacy & Policy Updates

Advocacy & Policy Updates

by | Apr 15, 2025

Advocacy & Policy Neuroendocrine Cancer UK was founded with the vision of providing support, raising awareness, and driving research for those affected by neuroendocrine cancer. What started as a small community initiative has now grown into a leading charity that...
NICE user involvement: NICE Prioritisation Board

NICE user involvement: NICE Prioritisation Board

by | Feb 18, 2025

The National Institute for Health and Care Excellence (NICE) set up the NICE Prioritisation Board to help decide topics for guidance development see more information. NICE are looking for two people to join the board to bring a perspective of patients, people who use...
Merkel Cell Carcinoma (MCC) Skin Cancer

Merkel Cell Carcinoma (MCC) Skin Cancer

by | May 28, 2021

Neuroendocrine Cancer UK is supporting Skin Cancer Awareness Month. Merkel cell carcinoma (MCC) is a rare, highly aggressive skin cancer, primarily affecting older patients, and thought to arise from the cutaneous Merkel cell, a neuroendocrine cell. The exact cause of...
Merkel Cell Carcinoma (MCC) Skin Cancer

Merkel Cell Carcinoma (MCC)

by | May 20, 2021

Neuroendocrine Cancer UK is supporting Skin Cancer Awareness Month.   Merkel cell carcinoma (MCC) is a rare, highly aggressive skin cancer, primarily affecting older patients, and thought to arise from the cutaneous Merkel cell, a neuroendocrine cell. The exact cause...
NICE approves Avelumab

NICE approves Avelumab

by | Apr 21, 2021

21st APRIL NICE APPROVES AVELUMAB Neuroendocrine Cancer UK is delighted to share with you NICE’s approval of Avelumab as a first line therapy option in metastatic MCC.  Avelumab is now recommended as an option for treating metastatic Merkel cell carcinoma in adults...